WO2024174957 - IL-15 AGONISTS FOR CANCER
National phase entry:
Publication Number
WO/2024/174957
Publication Date
29.08.2024
International Application No.
PCT/CN2024/077535
International Filing Date
19.02.2024
Title **
[English]
IL-15 AGONISTS FOR CANCER
[French]
AGONISTES D'IL-15 POUR TRAITER LE CANCER
Applicants **
REMEGEN CO., LTD.
No. 58 Beijing Middle Road, Yantai Development Zone, Yantai District, China (Shandong) Pilot Free Trade Zone
Yantai, Shandong 264006, CN
Inventors
WANG, Zhulun
650 Gateway Blvd., Suite #110, South San Francisco
California 94080, US
MIN, Xiaoshan
650 Gateway Blvd., Suite #110, South San Francisco
California 94080, US
CHEN, Hang
650 Gateway Blvd., Suite #110, South San Francisco
California 94080, US
Priority Data
63/486,185
21.02.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1417 | |
| EPO | Filing, Examination | 9729 | |
| Japan | Filing | 597 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5310 |
Total: 17628 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
Provided herein are IL-15/IL-15Rα-Fc fusion proteins that comprise an IL-15 receptor alpha sushi domain, an IL-15 C-terminal domain, an IL-15 N-terminal domain; and an Fc domain. Further provided are methods of using such IL-15/IL-15Rα-Fc to treat diseases and disorders, such as cancer.[French]
L'invention concerne des protéines de fusion IL-15/IL-15Rα-Fc qui comprennent un domaine alpha sushi du récepteur IL-15, un domaine C-terminal de IL-15, un domaine N-terminal de IL-15; et un domaine Fc. L'invention concerne en outre des procédés d'utilisation de telles IL-15/IL -15 Rα-Fc pour traiter des maladies et des troubles, tels que le cancer.